You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Lower 30- and 60-day mortality rates vs 7+31,a

30- and 60-day overall all-cause mortality in patients aged 60-75 (ITT population)1

30-day mortality rates in the Phase 3 trial of VYXEOS® for the treatment of AML-MRC and t-AML
60-day mortality rates in the Phase 3 trial of VYXEOS® for the treatment of AML-MRC and t-AML
  • 9 patients each in the VYXEOS arm (6%) and control arm (6%) had a fatal adverse reaction on treatment or within 30 days of therapy that was not in the setting of progressive disease1
  • 8 patients in the control arm (5%) died within 30 days of treatment due to progressive leukemia1
  • Fatal adverse reactions in the VYXEOS arm included infection, CNS hemorrhage, and respiratory failure1

Prolonged time to neutrophil and platelet recovery with VYXEOS1

Time to recovery of absolute neutrophil count and platelets may be prolonged with VYXEOS and require additional monitoring1

Learn about managing side effects that can be associated with VYXEOS treatment

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.